Global Genomics Partnering Terms and Agreements 2016 to 2023
The Global Genomics Partnering Terms and Agreements 2016-2023 report provides comprehensive understanding and unprecedented access to the genomics partnering deals and agreements entered into by the worlds leading healthcare companies.
The Global Genomics Partnering Agreements 2016-2023 report provides an understanding and access to the genomics partnering deals and agreements entered into by the worlds leading healthcare companies.
- Trends in genomics partnering deals
- Disclosed headlines, upfronts, milestones and royalties by stage of development
- Genomics partnering contract documents
- Top genomics deals by value
The Global Genomics Partnering Terms and Agreements 2016-2023 report provides an understanding and access to the genomics partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter genomics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors genomics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest genomics, oligonucletides including aptamers agreements announced in the healthcare sectors.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all genomics partnering deals announced since 2016 including financial terms where available including over 900 links to online deal records of actual genomics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
For example, analyzing actual company deals and agreements allows assessment of the following:
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What are the precise rights granted or optioned?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
The initial chapters of this report provide an orientation of genomics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in genomics dealmaking since 2016, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading genomics deals since 2016. Deals are listed by headline value, signed by big pharma, most active genomics dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in genomics dealmaking with a brief summary followed by a comprehensive listing of genomics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of genomics partnering deals signed and announced since Jan 2016, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of genomics partnering deals signed and announced since Jan 2016. The chapter is organized by specific genomics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided organized by genomics partnering company A-Z, deal type definitions and genomics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in genomics partnering and dealmaking since 2016.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of genomics technologies and products.
Global Genomics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to genomics trends and structure of deals entered into by leading companies worldwide.
Global Genomics Partnering Terms and Agreements includes:
- Trends in genomics dealmaking in the biopharma industry since 2016
- Access to headline, upfront, milestone and royalty data
- Access to over 800 genomics deals
- The leading genomics deals by value since 2016
- Most active genomics dealmakers since 2016
- The leading genomics partnering resources
In Global Genomics Partnering Terms and Agreements, the available contracts are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy and technology target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Global Genomics Partnering Terms and Agreements provides the reader with the following key benefits:
- In-depth understanding of genomics deal trends since 2016
- Access to headline, upfront, milestone and royalty data
- Comprehensive access to over 800 actual genomics deals entered into by the world’s biopharma companies, together with real world clause examples
- Full listing of genomics deals by company A-Z, deal value, phase of development, deal type, and therapy focus
- Identify leading genomics deals by value since 2016
- Identify the most active genomics dealmakers since 2016
- Detailed access to actual genomics contracts enter into by the leading bigpharma
- Insight into the terms included in genomics agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Chapter 1 – Introduction
Chapter 2 – Trends in genomics dealmaking
2.2. Genomics partnering over the years
2.3. Most active genomics dealmakers
2.4. Genomics partnering by deal type
2.5. Genomics partnering by therapy area
2.6. Deal terms for genomics partnering
2.6.1 Genomics partnering headline values
2.6.2 Genomics deal upfront payments
2.6.3 Genomics deal milestone payments
2.6.4 Genomics royalty rates
Chapter 3 – Leading genomics deals
3.2. Top genomics deals by value
Chapter 4 – Most active genomics dealmakers
4.2. Most active genomics dealmakers
4.3. Most active genomics partnering company profiles
Chapter 5 – Genomics contracts dealmaking directory
5.2. Genomics contracts dealmaking directory
Chapter 6 – Genomics dealmaking by technology type
Appendix 1 – Genomics deals by company A-Z
Appendix 2 – Genomics deals by stage of development
Appendix 3 – Genomics deals by deal type
Appendix 4 – Genomics deals by therapy area
Deal type definitions
Further reading on dealmaking
About Wildwood Ventures
Recent report titles from Current Partnering
Table of figures
Figure 1: Genomics partnering since 2016
Figure 2: Active genomics dealmaking activity since 2016
Figure 3: Genomics partnering by deal type since 2016
Figure 4: Genomics partnering by disease type since 2016
Figure 5: Genomics deals with a headline value
Figure 6: Genomics deals with an upfront value
Figure 7: Genomics deals with a milestone value
Figure 8: Genomics deals with a royalty rate value
Figure 9: Top genomics deals by value since 2016
Figure 10: Most active genomics dealmakers since 2016
- $3,995: single-user
- $5,745: multi-user
- $10,995: single site license
- $17,995: global site license
A full explanation of license type definitions can be found here.
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)
If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.
All card payments are processed by SagePay.
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
- Total Trust
Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.
1CellBiO, 1health.io, 2bPrecise, 2seventy bio, 3 Sisters Surrogacy, 4baseCare, 10X Genomics, 22nd Century, 23andMe, A*STAR Agency for Science, Technology and Research, A*STAR Bioinformatics Institute, A*STAR Genome Institute of Singapore, Abbvie, Abcam, ABL Diagnostics, Abramson Cancer Center, Absorption Systems, Academia Sinica, Accelerated Cure Project for MS, Accelerate Technologies, Access to Comprehensive Genomic Profiling Coalition, Acerta Pharma, ACMG Foundation for Genetic and Genomic Medicine, ACT Genomics, Active Motif, Adaptive Biotechnologies, ADInstruments, Admera Health, Adrestia, ADx Healthcare, Aevi Genomic Medicine, Affymetrix, AgBiome, Agendia, Agilent Technologies, Agribody Technologies, Agriplex Genomics, AiLife Diagnostics, Aitbiotech, Ajlan & Bros, Akadeum Life Sciences, Albany Molecular Research, Alexion Pharmaceuticals, AllCells, Almac Diagnostics, Alnylam Pharmaceuticals, ALS Automated Lab Solutions, Altor BioScience, Alzheimer's Drug Discovery Foundation, Amazon Web Services, Ambry Genetics, America's Choice Provider Network, American Physiological Society, American Society of Clinical Oncology (ASCO), American Type Culture Collection (ATCC), Amgen, Amplicon Express, Analytical BioSciences, Angsana Molecular & Diagnostics, AnimalBiome, APG Bio, Appistry, Applied Biosystems, Aptorum Group, Arbor Biotechnologies, Arc Bio, ArcherDX, Arcturus Therapeutics, Argonaut, Arima Genomics, ARUP Laboratories, Arzeda, Asa Ren, Aslan Pharma, Associazione Poic e Dintorni APS, Astellas Pharma, AstraZeneca, Astrea Forensics, Atlas Genomics, ATUM, Auria Biobank, Avance Biosciences, Avera Health, Avera Heart Hospital of South Dakota, Avvinity Therapeutics, B-MoGen Biotechnologies, Baheal Pharmaceutical, Bank of America, Banner Health, Basepair, BASF, Battelle, Bayer, Bayer CropScience, Baylor Genetics, Baylor Miraca Genetics Laboratories, BC Platforms, Beijing Genomics Institute (BGI), Beijing InnoCare Pharma, Belgian Society of Medical Oncology, Benson Hill Biosystems, Berkeley Lights, Berry Genomics, Beth Israel Deaconess Medical Center, BGI, BGI Americas, Bill and Melinda Gates Foundation, Bio-Rad Laboratories, Bio-Techne, BioBright, Biocartis, Biocore, Biodesix, BioDiscovery, Biogen, BioIntelliSense, BioIQ, BioLegend, BioMap, BioMarin Pharmaceutical, Biomedical Advanced Research and Development Authority, BioMed X Innovation Center, Biomillenia, BiomX, BioNano Genomics, BioSkryb, Biosplice, Biostar, BioTheranostics, BitBiome, Blackfynn, Blockchain Global, Bluebird Bio, Blue Cross Blue Shield Association, BluePen Biomarkers, BlueRock Therapeutics, Boca Biolistics, Boehringer Ingelheim, Bonnie J. Addario Lung Cancer Foundation, Bonsai Lab, Boreal Genomics, BostonGene, Boston Veterans Affair Research Institute, Bostwick Laboratories, Brammer Bio, Brigham and Women's Hospital, Bristol-Myers Squibb, Bristol-Myers Squibb Pakistan, Broad Institute, C2i Genomics, C3J Therapeutics, California Institute for Regenerative Medicine, California Institute of Technology, Calyxt, Cambridge Bioscience, Cambridge Cancer Genomics, CAMP4 Therapeutics, Canadian Cancer Society, Canadian Council, Cancer Genetics, Cancer Molecular Diagnostic Laboratory, Cancer Research Institute, Cancer Research UK, Canopy Biosciences, CareDx, Caribou Biosciences, Caris Life Sciences, Casebia Therapeutics, CasZyme, Celemics, Celgene, Cell and Gene Therapy Catapult, Cellecta, Cell Medica, Cellworks, Celmatix, Celsee, Celsius Therapeutics, Centauri Therapeutics, Center for Aquaculture Technologies, Center for Forensic Science Research & Education, Center for Molecular Medicine, Centers for Disease Control and Prevention, Centogene, Centre For Proteomic & Genomic Research, Centre for Research in Agricultural Genomics, CerebraCell, Ceva Sante Animale, CFTechnology.org, Champions Oncology, Chan Zuckerberg Initiative, Charles River Laboratories, Children's Hospital Boston, Children's Hospital Los Angeles, Children's Hospital of Philadelphia, Children's Medical Research Institute, Children's Mercy Hospital, Children's Minnesota, Children’s Hospital Oakland Research Institute (CHORI), Chinese Academy of Agricultural Science, Christian Doppler Research Association, ChromaCode, Chugai Pharmaceutical, Circuit Clinical, Citizens United for Research in Epilepsy, City of Hope, Clearbridge Biomedics, Cleveland Clinic, Cleveland Diagnostics, Clinical Genomics, Clinical Outcomes Tracking and Analysis, Cloudera, CloudHealth Genomics, Clover Therapeutics, CMT Research Foundation, Coastal Genomics, Codexis, Codigo46, Cofactor Genomics, Cohen Veterans Bioscience, Color, Colorado Center for Personalized Medicine, Color Genomics, Columbia University, CombiGene, Concr, Congenica, Contextual Genomics, CoreBiome, Core Diagnostics India, Coriell Life Sciences, Corteva Agriscience, Cosmo Bio, CosmosID, COTA, Courtagen Life Sciences, CRISPR Therapeutics, Crohn's and Colitis Foundation of America, CSI Laboratories, Culmination Bio, Curable, Curio Genomics, CvergenX, Cyclica, Cystic Fibrosis Foundation, Cystic Fibrosis Foundation Therapeutics, CYTOVIA Therapeutics, Cytox, D-Mark Biosciences, Dana-Farber Cancer Institute, Dante Genomics, Dante Labs, DAON BioSciences, Dartmouth-Hitchcock Medical Center, Data Tecnica International, Datavant, Decipher Biosciences, deCODE Genetics, DEEP 6 AI, Deep Genomics, Deerfield Management, Defense Advanced Research Projects Agency, DefiniGEN, Denali Therapeutics, Dendreon, Denka, Denka-KEW Genomics, Department of Veterans Affairs, DermTech, Desktop Genetics, DestiNA Genomics, Diamond Light Source, Dicom Systems, Discngine, DiscoveRx, Diversigen, DNA Electronics, DNA Link, DNAmito, DNAnexus, Dolomite Bio, Dovetail Genomics, Dow AgroSciences, DrChrono, Duke University, Duke University Health System, DuPont Pioneer, DxTerity, Eagle Genomics, ECOG-ACRIN Cancer Research Group, Edico Genome, EdiGene, Editas Medicine, Eisai Inc, Eisenberg Brothers, Eldan, Element Biosciences, Elevation Oncology, Eli Lilly, Elsevier, EMBRAPA, EMD Serono, Emedgene, Emendo Biotherapeutics, Empire Genomics, Enamine, EncrypGen, Ensoma, Enterome Bioscience, Enzyvant Science, Eone-Diagnomics Genome Center, Epic Sciences, Epilepsy Society, Epivax, ERS Genomics, Etubics, Eurofins Genomics, Eurofins Scientific, Euroimmun, European Commission, European Equity Partners, European Organization for Research and Treatment of Cancer, European Reference Genome Atlas, European Union, Evolva, Evonetix, Evotec, Evvy, Exact Sciences, Exonics Therapeutics, Exploragen, ExxonMobil, F1 Oncology, Fabric Genomics, Factorial Biotechnologies, Fauna Bio, FDNA, Ferring Pharmaceuticals, Fertility SOURCE Companies, FinnGen, First Databank, Flare Therapeutics, Flatiron Health, FLX Bio, FMC, Foundation for the Children of the Californias, Foundation Medicine, Frameshift Genomics, Fred & Pamela Buffett Cancer Center, Fred Hutchinson Cancer Research Center, Freenome, French National Institute for Agricultural Research, Front Range Biosciences, Fudan University, Fujitsu Laboratories, Fulcrum Therapeutics, Fulgent Genetics, Full Genomes, Fusion Genomics, G+FLAS Life Sciences, G-TAC, G42 Healthcare, GDM Seeds, GEDmatch, Gen9, Gencove, GeneBay, GeneCentric Therapeutics, Genective, GeneData, GeneDX, Geneformics, Genentech, GenePeeks, General Genomics, Genestack, Genetic Technologies, Genetiks, Genetron Health, Genewiz, GeneWorks, Genome Canada, GenomeDx, Genome Insight, Genome Institute of Singapore, Genome Medical, Genomenon, Genome Prairie, GenomeSmart, Genomic Biopharma, Genomic Health, Genomics, Genomics England, Genomic Testing Cooperative, Genomic Vision, Genomika, Genomind, Genomoncology, Genoox, Genoptix, Genosity, Genovis, GenScript Biotech, Gentris, Genuity Science, Genus, GenVec, GenXys, Georgetown Lombardi Comprehensive Cancer Center, Gilead Sciences, Ginkgo BioWorks, GlaxoSmithKline, Global Genomics Group, Goldfinch Bio, Google, Government of Canada, GPBio, Grail, Greater Paris University Hospitals, Gretel, Gritstone Bio, Guardant Health, H3 Biomedicine, Hackensack Meridian Health, Hackensack University Medical Center, Hamad Bin Khalifa University, Hamilton Robotics, Hangzhou Chengyuan Genomics Company, Harvard Stem Cell Institute, Harvard University, Healthcare Global Enterprises, HeartScore, Helen F Graham Cancer Center, Heligenics, Helix, Helmholtz Zentrum Munchen, HemaTone, Henry Ford Health System, Henry Schein, HepaTx, Hewlett Packard, HMNC Brain Health, Homology Medicines, Hong Kong Genome Institute, Hoosier Cancer Research Network, Horizon Discovery, Horizon Healthcare Services, Horizon Pharma plc, Hospital for Sick Children, Hospital for Special Surgery, Huawei, Hudson-Alpha Institute for Biotechnology, HudsonAlpha Institute for Biotechnology, Human Cell Atlas, Human Longevity, IBM, IBM Watson Health, Icahn School of Medicine at Mount Sinai, IDbyDNA, Idengene, ID Genomics, iGenomX, Illumina, ILUM Health Solutions, Imagene Labs, Imegen, Immune Design, Immunex, Imperial College London, Imperial Innovations, In-Depth Genomics, IncellDx, Incyte, Indiana University, Indivumed, IndyGeneUS AI, Information Technology for Translational Medicine, Inivata, INNOVASALUD, Innovate UK, Innovative Genomics Initiative (IGI), Inova Genomics Laboratory, Inova Labs, Inova Translational Medicine Institute, Insitro, Institute for Genome Statistics and Bioinformatics, Institute of Cancer Research, Institute of Human Genetics, Institut Gustave Roussy, Institut Pasteur, Integrated DNA Technologies, Intel, Intellia Therapeutics, Intelligence Advanced Research Projects Activity (IARPA), Intercept Pharmaceuticals, Intermountain Precision Genomics, International Myeloma Foundation, International Rice Research Institute, InterSystems, inviCRO, Invitae, Ionis Pharmaceuticals, Ipsen, IPS Genomix, IQVIA, iReceptor Plus, Isogen Life Science, ISOThrive, Israeli National Authority for Technological Innovation, Italian Government, Jackson Laboratory, Janssen Biotech, Janssen Pharmaceuticals, Jeffrey Modell Foundation, Johns Hopkins University, Johnson & Johnson Innovation, John Wayne Cancer Institute, Jumpcode Genomics, Kaiima Bio-Agritech, Kangmei Pharma, Kanteron Systems, Kapa Biosystems, Karolinska Institute, Kazusa DNA Research Institute, Keck School of Medicine of USC, KEW, Keygene, Kinetic Dx, King Abdullah International Research Center, Kleiner Perkins Caufield & Byers, Knudra Transgenics, KolGene, Konica Minolta Precision Medicine, KPMG, Kyowa Hakko Kirin, Kytopen, Lab Genomics, Laboratory Corporation of America, LaserGen, Lee Moffitt Cancer Center, Lenovo, Leona M and Harry B Helmsley Charitable Trust, Lesaffre, Les Laboratoires Servier, Leukemia & Lymphoma Society, LGC, LGS Foundation, Lieber Institute, Lifebit Biotech, Lifecode, LifeLabs Medical Laboratory Services, LifeNome, LifeOmic, Life Raft Group, Linus Biotechnology, Liquid Biotech USA, Locus Biosciences, Lodo Therapeutics, LogicBio Therapeutics, Longenesis, Lonza, Loop Genomics, Loxo Oncology, Lucigen, Lung Cancer Research Foundation, M3, Macrogen, Mainz Biomed, Marina Biotech, Massachusetts General Hospital, Massachusetts Institute of Technology, MassMutual, Mayo Clinic, MD Anderson Cancer Center, MDL Asia, Medaffcon, Medgenics, MedGenome, Medical University of Graz, Medicinal Genomics, Medley Genomics, MedStar Health Research Institute (MHRI), MedTek21, Meiogenix, Memorial Sloan Kettering Cancer Center, Mercachem, Merck and Co, Merck KGaA, Merus, Metabolon, Metagenomi, Metro Orthopedics and Sports Therapy, MGI Tech, Michael J Fox Foundation, Microba Life Sciences, Microbiotica, MicroGenDX, MicroMGx, Microsoft, Mikrogen, Millennium Science, Milner Therapeutics Institute and Consortium, MindImmune Therapeutics, MindX Sciences, Mirna Therapeutics, Mirus Bio, Mission Bio, Moderna, Molbio Diagnostics, Moleculera Labs, Monsanto, Montreal Heart Institute, MorphoSys, Movember Foundation, Multiplex Genomics, Munich Leukemia Laboratory, Myriad Genetics, Myrtelle, MyVytalics, N-of-One, Namocell, NanoCellect Biomedica, NantHealth, NantKwest, NantWorks, Nanyang Technological University, Nashville Biosciences, Natera, National Cancer Center, National Cancer Center of Japan, National Cancer Center of South Korea, National Cancer Institute, National Foundation for Cancer Research, National Geographic, National Health Service, National Human Genome Research Institute, National Institute for Health Research (NIHR), National Institute of Allergy and Infectious Diseases, National Institute of Child Health and Human Development, National Institute of Standards and Technology, National Institute on Drug Abuse (NIDA), National Institutes of Health, Navican, Nebula Genomics, NEC, Negen, Neogen, Neogenomics, Neptune Technologies & Bioressources, Netherlands Cancer Institute, Newborn Screening Ontario, New England Biolabs, NewStem, New York Genome Center (NYGC), New York Medical College, New York State Department of Health, NMI Natural and Medical Sciences Institute, Nomad Bioscience, Nonacus, NorthBay Healthcare, North Med, Northwestern University, Novartis, NovellusDx, Novogene, Novo Nordisk, Nrgene, Nvidia, Oklahoma Medical Research Foundation, Olink Bioscience, Omico, Omniome, OmniSeq, OncoDNA, Oncology Research Information Exchange Network, OncoMed Pharmaceuticals, Oncoshot, One BioMed, One Codex, One Lambda, Oneome, Onramp Bioinformatics, Ontario Institute for Cancer Research, OpenBench, Open Commons Consortium, Open Medicine Institute, OpGen, Opisafe, OPKO Health, Orchid Cellmark, Oregon Health Sciences University, ORIG3N, OrigiMed, Origin Agritech, Oryzon, Ovation Life Sciences, Oxford Biodynamics, Oxford Genetics, Ozyme, Pacific Biosciences, Paige, Pairwise Plants, Pancreatic Cancer Action Network, Pancreatic Cancer Collective, PapGene, Paradigm, Paragon Genomics, Parexel, Parse Biosciences, Partek, Partners HealthCare, PathGroup, PathoQuest, Pathway Genomics, PerkinElmer, Personal Genome Diagnostics, Personalis, PersonalizeDx, PetaGene, Pfizer, Pharmatest Services, Pharnext, Phase Genomics, Phenome Networks, Philips, Phosphorus Genomics, Pierian, PierianDx, Pillar Biosciences, Pioneer Hi-Bred, Plant Bioscience Limited, Pluristem Therapeutics, Portable Genomics, Poseida Therapeutics, Positive Bioscience, Precision Biologics, Precision BioSciences, Precision NanoSystems, Predicine, Premier Inc, Prenetics, Prescient Medical, PreventionGenetics, Primetech, Progknowse, PrognomIQ, Promega, Prophase Labs, Prostate Cancer Clinical Trials Consortium, Prostate Cancer Foundation (PCF), Protean BioDiagnostics, Proteigene, Proteostasis Therapeutics, Proteus Genomics, Pryzm Health, Psomagen, Purigen, PWNHealth, Q2 Solutions, Qatar Foundation, Qiagen, Quanterix, Quantgene, QuantumDx, Quark Pharmaceuticals, Quest Diagnostics, Quintara Biosciences, R-Biopharm, rAAVen Therapeutics, Rady Children's Institute for Genomic Medicine, Rainbow Genomics, Rain Therapeutics, Rare Genomics Institute, Recombia Biosciences, Regeneron Genetics Center, Regeneron Pharmaceuticals, Replicate Bioscience, Replicel Life Sciences, Repositive, Research Instruments, Reveal Genomics, Rhenium, RIKEN Center for Integrative Medical Sciences, Ripe Technology, Robert H. Lurie Comprehensive Cancer Center, Roche, Roche Diagnostics, Rockefeller University, Rosetta Genomics, Royal Philips Electronics, RPRD Diagnostics, RTI International, Rubicon Genomics, Rutgers University, S2 Genomics, SAGA Diagnostics, Salk Institute, Salud Interactiva, Sana Biotechnology, Sangamo Therapeutics, Sanguine, Sanofi, Saol Therapeutics, Sapio Sciences, Sarah Cannon Research Institute, Sarepta Therapeutics, Scarab Genomics, Science Exchange, Scripps Research Institute, Scripps Translational Science Institute, SCRUM, Second Genome, Seer, Sema4, Semmelweis University, Sentieon, SenzaGen, Seoul National University, Seqster, Sequanta, SeQure Dx, SeqWell, Seracare Life Sciences, Seres Therapeutics, Serotiny, Seven Bridges Genomics, SGI-DNA, Shanghai ChemPartner, Shanghai Institutes of Preventative Medicine, Shanghai Titan Scientific, Shardna, Sheba Medical Center, Shire Laboratories, Shivom, Singlera Genomics, Singleron Biotechnologies, Singular Genomics Systems, Skane University Hospital, SkylineDX, SOLTI, SolveBio, SomaGenics, Sonic Healthcare, Sophia Genetics, Sosei Heptares, SouthGenetics, Spanish National Cancer Research Centre, Spatial Genomics, Sphere Fluidics, SPT Labtech, St. Jude Children's Research Hospital, StageDotO, Stanford University, Stanford University School of Medicine, Stratify Genomics, Streck Laboratories, Structural Genomics Consortium, Sunnybrook Research Institute, SunTerra Biotechnology, Susan G. Komen for the Cure, Swift Biosciences, Syapse, Synbio, Syngenta, Synthego, Synthetic Genomics, Syros Pharmaceuticals, Sysmex Inostics, Taconic Biosciences, Tagaca, Taiwan Precision Medicine Initiative, Takara Bio, Takeda Pharmaceutical, Takeda Ventures, Tango Therapeutics, TARGET PharmaSolutions, Tavros Therapeutics, Technology University Dresden, Techtum Lab, Tempus, Tenet Diagnostics, Tesis Biosciences, Tessera Therapeutics, The Donor Solution, The New York Stem Cell Foundation, The Parker Institute For Cancer Immunotherapy, Theraly Fibrosis, Thermo Fisher Scientific, The Silverstein Foundation for Parkinson's, The University of Chicago Medicine, The World Egg Bank, Thrive Bioscience, Tiziana Life Sciences, TMA Precision Health, TME Research, Tokyo Medical and Dental University, TOMA Biosciences, Tomy Digital Biology, Tow Foundation, Toyota Motor, Transcriptic, Transcriptome Sciences, Transgene, Transgenomic, Translational Drug Development, Translational Genomics Research Institute, Translational Software, Transplant Genomics, Tree Code, TrovaGene, Tute Genomics, Twinstrand Therapeutics, Twist Bioscience, Two Blades Foundation, uBiome, UbiQ, UK Biobank, Ultima Genomics, Unilabs, Univeristy of Durham, University College Dublin Conway Institute, University College London, University Health Network, University Hospital of Leuven, University Magna Graecia, University of Adelaide, University of Birmingham, University of Bonn, University of British Columbia, University of Buffalo, University of Calgary, University of California, University of California, Davis, University of California, San Diego, University of California Berkeley, University of California Los Angeles, University of California San Francisco, University of California Santa Cruz, University of Colorado Denver, University of Edinburgh, University of Greifswald, University of Hong Kong, University of Iowa, University of Leuven, University of Manchester, University of Miami, University of Michigan, University of Michigan Medical School, University of Nebraska, University of Pennsylvania, University of Pittsburgh, University of Rostock, University of Siena, University of Texas Southwestern Medical Center, University of Tokyo, University of Tubingen, University of Utah, University of Virginia, University of Washington, University of Western Australia, US Oncology, Utah Genome Project, ValGenesis, Vanderbilt University, Vantari Genetics, Varian Medical Systems, Vectalys, Ventana Medical Systems, Veracyte, Verge Genomics, Veritas, Veritas Genetics, Verogen, Vertex Pharmaceuticals, VieCure, Vikor Scientific, Vir Biotechnology, Vitaccess, Viviphi, Vivo Biosciences, Voyager Therapeutics, VWR International, WaferGen Biosystems, Wageningen University, Warp Drive Bio, Washington University in St Louis, Watchmaker Genomics, Wayne State University, Weill Cornell Medical College, Wellcome Trust Sanger Institute, Western Digital, Wuxi Apptec Laboratory Services, WuXi NextCODE Genomics, Xcell Biosciences, xD Bio, Xencor, XIFIN, Xpressomics, Yale School of Medicine, Yale University, Yield10 Bioscience, ZeptoMetrix, Zhengzhou University, Zymergen, Zymo Research
Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.
The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Collaborative R&D
• Contract service
• Equity purchase
• Joint venture
• Royalty financing
• Spin out
• Sub license
Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.